Company news

AstraZeneca PLC news in 2018

AstraZeneca PLC's news releases, calls and decks from 2018, newest first.

View company

AZ: positive CHMP for Tagrisso first-line nsclc

April 27, 2018

AstraZeneca: high level results of the ARCTIC trial

April 24, 2018

FDA approves Tagrisso for 1st-line use in NSCLC

April 19, 2018

FDA to review moxetumomab for Hairy cell leukaemia

April 3, 2018

Az and MSD submit Lynparza for breast cancer in eu

April 3, 2018

Lokelma approved in the EU

March 22, 2018

AstraZeneca updates MYSTIC trial timeline

March 12, 2018

Lynparza CHMP for ovarian cancer maintainance

February 23, 2018

AstraZeneca's IMFINZI approved for Stage III nsclc

February 19, 2018

Selumetinib in NF1 gets FDA orphan drug status

February 15, 2018

AZN: Full-Year 2017 Results

February 2, 2018

AZ Reports Phase III Results for PT010 in COPD

January 26, 2018

Lynparza approved in Japan for ovarian cancer

January 19, 2018

AstraZeneca's Fasenra receives approval in Japan

January 19, 2018

FDA approves Lynparza for metastatic breast cancer

January 12, 2018

AstraZeneca's Fasenra approved in the EU

January 10, 2018

← Newer news releases

Decks in 2018